Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.28.6.657
Abstract: BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. Despite the high unmet need for patients with HER2+ MBC… read more here.
Keywords: seagen inc; seagen; patients her2; among patients ... See more keywords
Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2023.29.3.314
Abstract: BACKGROUND: The ECHELON-2 5-year update showed continued clinically meaningful improvements in progression-free survival (PFS) and overall survival with frontline (1L) A+CHP (brentuximab vedotin in combination with cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)… read more here.
Keywords: oncology; progression free; utilization; chp ... See more keywords